Holen Sie sich die Stockscreener-App
238.97
1.35%
-3.26
Handel nachbörslich:
238.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$242.23
Offen:
$241.54
24-Stunden-Volumen:
2.52M
Relative Volume:
2.23
Marktkapitalisierung:
$33.61B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
23.04
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
+3.88%
1M Leistung:
+4.70%
6M Leistung:
+6.34%
1J Leistung:
-11.49%
1-Tages-Spanne:
$237.87
$242.57
1-Wochen-Bereich:
$230.08
$242.63
52-Wochen-Spanne:
$180.26
$277.67
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-08-19 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2026-07-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-07-13 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-06-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Mizuho Adjusts Price Target on ResMed to $240 From $235 - www.marketscreener.com
EBITDA of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Q4 2026 Earnings Call Transcript - Benzinga
Is ResMed Facing Fresh Questions Before Results (ASX:RMD)? - Kalkine Media
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com South Africa
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com Nigeria
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Form 4 ResMed Inc For: 8 October By Investing.com - Investing.com Nigeria
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed (NYSE:RMD) Stock: Insider Michael Farrell Sells 4,991 Shares - MarketBeat
ResMed chairman & CEO Michael Farrell sells $1.1m in shares - Investing.com
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
What Is Shaping Breville, Treasury Wine and ResMed? - Kalkine Media
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Michael Farrell proposes selling 4,991 ResMed (NYSE: RMD) shares through Fidelity. - Stock Titan
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals - ChartMill
ResMed plans USD 1.5 billion share repurchase and RBC raises target for ResMed stock - ad-hoc-news.de
Resmed (ASX:RMD) Shares Slide Over the Year Even as Record Q4 Revenue and a Higher Dividend Close Fiscal 2026 - Kalkine
ResMed stock pre-market at EUR 199.20: plus 0.48 percent - ad-hoc-news.de
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
ResMed Inc Reports CDI and Common Stock Movements for September 2026 - Kalkine
RSMDF | RESMED INC ORD Insider Trading - Quiver Quantitative
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Stifel reiterates Hold on ResMed stock amid market share concerns - Investing.com
ResMed Inc. $RMD Shares Sold by Envestnet Asset Management Inc. - MarketBeat
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC SEC Filing (Oct 1, 2026) - Stock Titan
Form 4 ResMed Inc For: 1 October By Investing.com - Investing.com Nigeria
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan. - Stock Titan
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 - Moomoo
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Form ARS RESMED INC For: Jun 30 - StreetInsider
Will ResMed (ASX:RMD) stay a fund manager favourite? - Kalkine Media
Price to cash flow ratio of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed stock trades at EUR 195.18 after RBC raises target - AD HOC NEWS
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator? - Kalkine Media
Net debt of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Resmed Inc-Aktie (RMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Sale |
226.33 |
4,991 |
1,129,637 |
479,803 |
| Farrell Michael J. | Officer |
Oct 07 '26 |
Proposed Sale |
226.33 |
4,991 |
1,129,638 |
0 |
| Farrell Michael J. | Officer |
Sep 08 '26 |
Proposed Sale |
226.22 |
4,991 |
1,129,064 |
0 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Sale |
222.44 |
4,991 |
1,110,191 |
466,256 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| FARRELL PETER C | Director |
Sep 02 '26 |
Sale |
234.73 |
970 |
227,688 |
51,803 |
| Peter C Farrell | Director |
Sep 02 '26 |
Proposed Sale |
234.65 |
970 |
227,608 |
0 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Sale |
205.69 |
4,991 |
1,026,596 |
466,256 |
| Farrell Michael J. | Officer |
Aug 07 '26 |
Proposed Sale |
205.69 |
4,991 |
1,026,596 |
0 |
0.60%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):